Vaxcyte Q2 2023 Earnings Report

Vaxcyte EPS Results

• Actual EPS: -$0.70
• Consensus EPS: -$0.74
• Beat/Miss: Beat by +$0.04
• One Year Ago EPS: N/A

Vaxcyte Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vaxcyte Announcement Details

• Quarter: Q2 2023
• Date: 8/8/2023
• Time: After Market Closes

Vaxcyte (NASDAQ:PCVX), a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.